Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Dokumenty

L0551000

Levonorgestrel

European Pharmacopoeia (EP) Reference Standard

Synonim(y):

D(−)-Norgestrel, 13β-Ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one, 17α-Ethynyl-18-homo-19-nor-testosterone, 18,19-Dinor-13β-ethyl-17β-hydroxy-4-pregnen-20-yn-3-one, 18,19-Dinor-4-pregnen-20-yn-3-one, Levonorgestrel

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C21H28O2
Numer CAS:
797-63-7
Masa cząsteczkowa:
312.45
Numer MDL:
MFCD00199013
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329817365
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

levonorgestrel

producent / nazwa handlowa

EDQM

Zastosowanie

pharmaceutical (small molecule)

format

neat

ciąg SMILES

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

Klucz InChI

WWYNJERNGUHSAO-XUDSTZEESA-N

informacje o genach

human ... PGR(5241)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Powiązane kategorie

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Levonorgestrel EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Sales restrictions may apply.

Piktogramy

Health hazard
GHS08

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

H351,H360D,H362

Zwroty wskazujące środki ostrożności

P202 - P260 - P263 - P264 - P270 - P308 + P313

Klasyfikacja zagrożeń

Carc. 2 - Lact. - Repr. 1A

Kod klasy składowania

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Choose from one of the most recent versions:

Certyfikaty analizy (CoA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

Slide 1 of 10

1 of 10

Dienogest European Pharmacopoeia (EP) Reference Standard

Y0001785

Dienogest

Drospirenone ≥98% (HPLC)

Sigma-Aldrich

SML0147

Drospirenone

Desogestrel Related Compound C United States Pharmacopeia (USP) Reference Standard

USP

1173268

Desogestrel Related Compound C

Desogestrel impurity D British Pharmacopoeia (BP) Reference Standard

BP816

Desogestrel impurity D

D(−)-Norgestrel analytical standard

Supelco

N2260

D(−)-Norgestrel

Norethisterone European Pharmacopoeia (EP) Reference Standard

N1200000

Norethisterone

Ethinylestradiol British Pharmacopoeia (BP) Assay Standard

BP421

Ethinylestradiol

Etonogestrel ≥98% (HPLC)

Sigma-Aldrich

SML0356

Etonogestrel

Ethinyl Estradiol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1480

Ethinyl Estradiol

17α-Ethynylestradiol ≥98%

Sigma-Aldrich

E4876

17α-Ethynylestradiol

Abbey B Berenson et al.
Obstetrics and gynecology, 121(5), 951-958 (2013-05-03)
Many U.S. health care providers remain reluctant to prescribe intrauterine devices (IUDs) to teenagers as a result of concerns about serious complications. This study examined whether 15-19-year-old IUD users were more likely to experience complications, failure, or early discontinuation than
Anita Nelson et al.
Obstetrics and gynecology, 122(6), 1205-1213 (2013-11-19)
To evaluate the efficacy and safety of two low-dose levonorgestrel intrauterine contraceptive systems. Nulliparous and parous women aged 18-35 years with regular menstrual cycles (21-35 days) requesting contraception were randomized to 3 years of treatment with one of two levonorgestrel
Ioannis D Gallos et al.
Obstetrics and gynecology, 121(6), 1165-1171 (2013-07-03)
To identify predictors and to estimate their prognostic accuracy for regression and relapse of endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system or oral progestogens. This was a cohort study of women treated with levonorgestrel-releasing intrauterine system or oral progestogens for
Virpi Koskela-Niska et al.
International journal of cancer, 133(7), 1680-1688 (2013-03-26)
Postmenopausal hormone therapy (HT) associates with an increased risk of ovarian cancer, but its' influence on tumor histology is not as well known. Therefore, we evaluated the effect of various types of HT on the risk of epithelial ovarian cancer
H K Kroupova et al.
Aquatic toxicology (Amsterdam, Netherlands), 154, 154-162 (2014-06-04)
The aim of the present study was to investigate the effects of the synthetic progestin levonorgestrel (LNG) on the reproductive endocrine system of a teleost fish, the roach (Rutilus rutilus). Pubertal roach were exposed for 28 days in a flow-through
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej